Hexvix is an optical imaging agent developed by the Norwegian pharmaceutical company Photocure ASA.
Hexvix was FDA approved in the US in May 2010 under the tradename Cysview.
•
Photocure was founded in 1993 and Photocure's aim was to commercialise photodynamic technologies developed by the Norwegian Radium Hospital, the largest comprehensive cancer centre in Northern Europe.
•
Cysview (hexaminolevulinate) for diagnosis of bladder cancer.